Optimization of HPMC and carbopol concentrations in non-effervescent floating tablet through factorial design.

This study was to optimize HPMC K4M and carbopol 934 concentration in the development of non-effervescent floating tablets (NEFTs) of glipizide as model drug using 3(2) factorial design. The time required for releasing drug of 50% and 80% and similarity factor were the target responses. HPMC K4M and carbopol 934 concentrations were the variables. The response surface methodology and optimized polynomial equations were used to select the optimal formulation with desired responses. The excipients used in tablets were compatible with glipizide as per the results of isothermal stress testing and DSC study. The drug release of entire NEFTs followed zero order kinetics and non-Fickian diffusion mechanism. Validation of the optimization technique demonstrated the reliability of the model. The optimized formulation containing 124.33 mg HPMC K4M and 25.76 mg carbopol 934 was prepared according to the software determined levels. The stability study of the optimized formulation proved the integrity of the developed formulation.

Development and validation of RP-HPLC method for quantification of glipizide in biological macromolecules.

Glipizide (GPZ) has been widely used in the treatment of type-2 diabetics as insulin secretogague. Multiunit chitosan based GPZ floating microspheres was prepared by ionotropic gelation method for gastroretentive delivery using sodiumtripolyphosphate as cross-linking agent. Pharmacokinetic study of microspheres was done in rabbit and plasma samples were analyzed by a newly developed and validated high-performance liquid chromatographic method. Method was developed on Hypersil ODS-18 column using a mobile phase of 10mM phosphate buffer (pH, 3.5) and methanol (25:75, v/v). Elute was monitored at 230 nm with a flow rate of 1 mL/min. Calibration curve was linear over the concentration range of 25.38-2046.45 ng/mL. Retention times of GPZ and internal standard (gliclazide) were 7.32 and 9.02 min respectively. Maximum plasma drug concentration, area under the plasma drug concentration-time curve and elimination half life for GPZ floating microspheres were 2.88±0.29 µg mL(-1), 38.46±2.26 µg h mL(-1) and 13.55±1.36 h respectively. When the fraction of drug dissolved from microspheres in pH 7.4 was plotted against the fraction of drug absorbed, a linear correlation (R(2)=0.991) was obtained in in vitro and in vivo correlation study.

Compatibility studies of nateglinide with excipients in immediate release tablets.

Experiments were done to assess the compatibility of nateglinide with selected excipients in the development of immediate release tablets of nateglinide by thermal and isothermal stress testing (IST) techniques. To evaluate the drug-excipient compatibility, different techniques such as differential scanning calorimetric (DSC) study, infra-red (IR) spectrophotometric study and isothermal stress testing were adopted. The results of DSC study showed that magnesium stearate exhibited some interaction with nateglinide. However, the results of IR, and IST studies showed that all the excipients used in the formula were compatible with nateglinide. Optimized formulations developed using the compatible excipients were found to be stable over 3 months of accelerated stability studies (40 ± 2°C and 75 ± 5% RH). Overall, compatibility of excipients with nateglinide was successfully evaluated using a combination of thermal and IST methods and the formulations developed using the compatible excipients were found to be stable.